Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,326-2,350 of 3,186
CompletedNCT04846881

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Argentina, Brazil, Chile, Croatia, France, Hungary, Japan, Malaysia, Netherlands, Poland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain, Ukraine, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT05741528

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT05628103

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT01964404

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Dartmouth-Hitchcock Medical Center
Condition
Schizophrenia
CompletedNCT04147897

Implementing mHealth for Schizophrenia in Community Mental Health Settings

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand what helps a digital app or remote support tool stay useful, realistic, and easier to follow over time.

SchizophreniaOtherFrom 18 Years to 100 Years
Countries
United States
Sponsor
University of Washington
Condition
Schizophrenia
CompletedNCT06061952

CAE for Poorly Adherent Individuals With Schizophrenia

This study exists to see whether questionnaires and follow-up reports is workable and worth testing more broadly. Researchers are trying to understand whether questionnaires and follow-up reports can make support easier to access outside standard clinic visits.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
University Hospitals Cleveland Medical Center
Condition
Schizophrenia
CompletedNCT04779177

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

This study exists to better understand the safety of this type of care and how manageable it feels in practice. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
CompletedNCT04846868

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Australia, Brazil, Canada, China, Colombia, Germany, Greece, Italy, Japan, Mexico, New Zealand, Norway, Philippines, Poland, Sweden, Turkey, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT04317807

R33: Levetiracetam in Early Psychosis

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 16 Years to 40 Years
Countries
United States
Sponsor
NYU Langone Health
Condition
Schizophrenia
CompletedNCT06179108

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

This study exists to compare options and see whether the medication LB-102 offers something meaningfully different. Researchers are trying to understand how people respond to the medication LB-102 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
LB Pharmaceuticals Inc.
Condition
Schizophrenia
CompletedNCT06067984

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Click Therapeutics, Inc.
Condition
Schizophrenia
CompletedNCT04457310

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

This study exists to understand what helps blood tests and biological markers work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT04557124

USS Training to Improve Social Function in People With Psychosis

This study exists to explore whether acceptance and commitment therapy, a talking treatment, could improve care and understanding. Researchers are trying to understand what acceptance and commitment therapy, a talking treatment, could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
SuspendedNCT03930251

Cognitive Remediation for Coordinated Specialty Care

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 30 Years
Countries
United States
Sponsor
New York State Psychiatric Institute
Condition
Schizophrenia
CompletedNCT01499563

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

This study exists to compare options and see whether the medication ITI-007 offers something meaningfully different. Researchers are trying to understand how people respond to the medication ITI-007 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
CompletedNCT00587561

Efficacy of Social Cognition Training in Schizophrenia

This study exists to see whether a guided support group can make care clearer and more responsive. Researchers are trying to understand whether a guided support group can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
VA Connecticut Healthcare System
Condition
Schizophrenia
CompletedNCT05538832

Remote State Representation in Early Psychosis

This study exists to learn from real-world information that can show how a digital app or remote support tool fits into care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 30 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
CompletedNCT02469155

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

This study exists to compare options and see whether the medication ITI-007 offers something meaningfully different. Researchers are trying to understand what the medication ITI-007 could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
CompletedNCT02282761

A Trial to Assess the Antipsychotic Efficacy of ITI-007

This study exists to compare options and see whether the medication ITI-007 offers something meaningfully different. Researchers are trying to understand what the medication ITI-007 could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
CompletedNCT07190352

Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia

This study exists to see whether smoking support or smoking-related treatment can play a useful role in care. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia
CompletedNCT05273164

State Representation in Early Psychosis

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 15 Years to 45 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
TerminatedNCT06002958

Horyzons: Implementation and Integration in Clinical Practice

This study exists to see whether a guided support group can play a useful role in care. Researchers are trying to understand whether a guided support group can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 16 Years to 35 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia